VXRT Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals, Inc. has a net margin of -11.24% compared to Vaxart, Inc.'s net margin of -2301.55%. Vaxart, Inc.'s return on equity of -108.98% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Vaxart, Inc. has a consensus price target of $3.33, signalling upside risk potential of 863.39%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 36.78%. Given that Vaxart, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Vaxart, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Vaxart, Inc. has a beta of 0.877, which suggesting that the stock is 12.277% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Vaxart, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxart, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Vaxart, Inc. quarterly revenues are $72.4M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Vaxart, Inc.'s net income of -$8.1M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Vaxart, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxart, Inc. is 0.53x versus 54.58x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bionano Genomics, Inc. has a net margin of -11.24% compared to Vaxart, Inc.'s net margin of -115.42%. Vaxart, Inc.'s return on equity of -108.98% beat Bionano Genomics, Inc.'s return on equity of -84.77%.

Vaxart, Inc. has a consensus price target of $3.33, signalling upside risk potential of 863.39%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 393.42%. Given that Vaxart, Inc. has higher upside potential than Bionano Genomics, Inc., analysts believe Vaxart, Inc. is more attractive than Bionano Genomics, Inc..

Vaxart, Inc. has a beta of 0.877, which suggesting that the stock is 12.277% less volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 2.336, suggesting its more volatile than the S&P 500 by 133.592%.

Vaxart, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxart, Inc. pays -- of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend.

Vaxart, Inc. quarterly revenues are $72.4M, which are larger than Bionano Genomics, Inc. quarterly revenues of $7.4M. Vaxart, Inc.'s net income of -$8.1M is higher than Bionano Genomics, Inc.'s net income of -$8.5M. Notably, Vaxart, Inc.'s price-to-earnings ratio is -- while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxart, Inc. is 0.53x versus 0.18x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of -11.24% compared to Vaxart, Inc.'s net margin of -12425.36%. Vaxart, Inc.'s return on equity of -108.98% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Vaxart, Inc. has a consensus price target of $3.33, signalling upside risk potential of 863.39%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 327.35%. Given that Vaxart, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Vaxart, Inc. is more attractive than Perspective Therapeutics, Inc..

Vaxart, Inc. has a beta of 0.877, which suggesting that the stock is 12.277% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Vaxart, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxart, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Vaxart, Inc. quarterly revenues are $72.4M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Vaxart, Inc.'s net income of -$8.1M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Vaxart, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxart, Inc. is 0.53x versus 195.28x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -11.24% compared to Vaxart, Inc.'s net margin of 13.19%. Vaxart, Inc.'s return on equity of -108.98% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Vaxart, Inc. has a consensus price target of $3.33, signalling upside risk potential of 863.39%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 507.74%. Given that Vaxart, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe Vaxart, Inc. is more attractive than Protalix Biotherapeutics, Inc..

Vaxart, Inc. has a beta of 0.877, which suggesting that the stock is 12.277% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Vaxart, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxart, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Vaxart, Inc. quarterly revenues are $72.4M, which are larger than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Vaxart, Inc.'s net income of -$8.1M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Vaxart, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 26.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxart, Inc. is 0.53x versus 2.30x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.